Orbicular Pharmaceutical Technologies

Hyderabad, India Founded: 2010 • Age: 16 yrs
Manufacturer of niche generic and specialty pharmaceutical products

About Orbicular Pharmaceutical Technologies

Orbicular Pharmaceutical Technologies is a Healthcare company based in Hyderabad (India) founded in 2010 by M.S. Mohan and Hiren Patel. Manufacturer of niche generic and specialty pharmaceutical products. Orbicular Pharmaceutical Technologies has raised $20 million across 1 funding round from investors including Tata Capital Healthcare Fund. The company has 218 employees. Its Indian entity Orbicular Pharmaceutical Technologies Private Limited reported revenue of ₹262 Cr. Orbicular Pharmaceutical Technologies offers products and services including Complex Injectables, Topicals, Ophthalmics, Nasal Sprays, and Inhalations. Its focus areas include Diversified Pharmaceuticals and Drugs.

Company details

Orbicular Pharmaceutical Technologies was established in 2010 and is based in Hyderabad, India. Operations focus on the pharmaceutical sector, where niche generic and specialty products are produced. These include injectables, topicals, ophthalmics, parenterals, nasal sprays, and inhalation formulations. Advanced technologies such as microspheres, nanosuspensions, nano-emulsions, liposomes, and peptides are utilized in manufacturing processes.

Key Metrics
  • Annual Revenue
    ₹262 Cr

    FY 2025 · +41% YoY

  • Net Profit
    ₹28.36 Cr

    FY 2025 · 10% margin

  • EBITDA
    ₹96.66 Cr

    FY 2025 · 36% margin

  • Total Equity Funding
    $20M (USD)

    in 1 rounds

  • Latest Funding Round
    $20M (USD), Private Equity Round

    May 2024

  • Investors
  • Employee Count
    218

Products & Services of Orbicular Pharmaceutical Technologies

Orbicular Pharmaceutical Technologies offers a comprehensive portfolio of products and services, including Complex Injectables, Topicals, Ophthalmics, Nasal Sprays, and Inhalations.

Complex Injectables
Injectables

Developed for niche generic pharmaceutical applications.

Topicals
Topical Medications

Formulations for skin and external drug delivery.

Ophthalmics
Eye Care Products

Specialty drugs for ocular treatments and applications.

Nasal Sprays
Respiratory Products

Delivery systems for nasal medication administration.

Inhalations
Respiratory Products

Formulations for inhalation-based drug delivery.

Funding Insights of Orbicular Pharmaceutical Technologies

Orbicular Pharmaceutical Technologies has successfully raised a total of $20M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $20 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $20M
  • Total Rounds 1
  • Last Round Private Equity Round — $20M
  • First Round $20M

    (May 2024)

  • Investors Count 1

All 1 funding rounds of Orbicular Pharmaceutical Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2024$20MPrivate Equity Round–TCHF
–
Valuation history

1 investors in total: 1 institutional.

Investors in Orbicular Pharmaceutical Technologies

Orbicular Pharmaceutical Technologies has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Tata Capital Healthcare Fund.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Private equity fund investing in healthcare and lifesciences in India.
2021tatacapitalhealthcarefund.comMumbai, India
Premium access

Investor details for Orbicular Pharmaceutical Technologies

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Orbicular Pharmaceutical Technologies Private Limited (Orbicular Pharmaceutical Technologies)

Orbicular Pharmaceutical Technologies Private Limited is the primary company behind Orbicular Pharmaceutical Technologies. The board of Orbicular Pharmaceutical Technologies Private Limited currently have 6 directors; the longest-serving is Meena Mohan, appointed in 2008. 5 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Meena Mohan
DIN 02121102
Director13 Aug 200818 yrs 3 moOrbicular Pharmaceutical Technologies Private Limited
Sivaraman Mohan Mailatur
DIN 02573448
Managing Director06 Aug 201016 yrs 3 moOrbicular Pharmaceutical Technologies Private Limited
Hiren Dasharathbhai Patel
DIN 03560495
Director24 Aug 201214 yrs 2 moOrbicular Pharmaceutical Technologies Private Limited
Rahul Gawande Sudhakar
DIN 07477010
Director01 Jul 20197 yrs 4 moOrbicular Pharmaceutical Technologies Private Limited
Bhaveshkumar Vallabhbhai Patel
DIN 07932528
Director01 Apr 20224 yrs 7 moOrbicular Pharmaceutical Technologies Private Limited
Visalakshi Chandramouli
DIN 03594109
Nominee Director31 May 20242 yrs 5 moOrbicular Pharmaceutical Technologies Private Limited

People of Orbicular Pharmaceutical Technologies

2 people are tracked at Orbicular Pharmaceutical Technologies (2 in leadership); the tracked headcount is 218.

NameRoleGroup
M.S. Mohan
Co-Founder & MDLeadership
Co-Founder & PresidentLeadership
Premium access

Complete people profiles for Orbicular Pharmaceutical Technologies

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Orbicular Pharmaceutical Technologies

Figures of Orbicular Pharmaceutical Technologies Private Limited, the primary company behind Orbicular Pharmaceutical Technologies, for FY 2025. Revenue was ₹262 Cr (+41% year on year). Net profit was ₹28.36 Cr (10% margin). EBITDA was ₹96.66 Cr (36% margin). Revenue has grown at a compounded annual rate of +6% over three years.

  • ₹262 CrRevenue · FY 2025 · +41% YoY
  • ₹28.36 CrNet profit · 10% margin
  • ₹96.66 CrEBITDA · 36% margin
  • ₹11.18 CrPaid-up capital
  • 253Employees (provident fund records)
  • +6%Revenue CAGR, 3 years

Balance sheet, profit and loss, cash flow and ratios of Orbicular Pharmaceutical Technologies Private Limited are on its company page.

Premium access

Detailed financial statements for Orbicular Pharmaceutical Technologies

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Orbicular Pharmaceutical Technologies

2 dated milestones of Orbicular Pharmaceutical Technologies across 14 years, from founding to its latest funding, stage changes and deals.

  1. Founded Orbicular Pharmaceutical Technologies is founded.
  2. Funding First funding round of $20.0M.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Orbicular Pharmaceutical Technologies

Premium access

Complete news archive for Orbicular Pharmaceutical Technologies

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Orbicular Pharmaceutical Technologies

Orbicular Pharmaceutical Technologies was founded in 2010 and raised its 1st funding round 14 years after it was founded.

Orbicular Pharmaceutical Technologies is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Orbicular Pharmaceutical Technologies is a funded company, having raised a total of $20M across 1 funding round to date. The company's 1st funding round was a Private Equity Round of $20M, raised on May 2024.

Orbicular Pharmaceutical Technologies has 218 employees.

The primary company behind Orbicular Pharmaceutical Technologies, Orbicular Pharmaceutical Technologies Private Limited, reported revenue of ₹262 Cr for FY 2025, up 41% year on year.

Orbicular Pharmaceutical Technologies was established in 2010 and is based in Hyderabad, India. Operations focus on the pharmaceutical sector, where niche generic and specialty products are produced. These include injectables, topicals, ophthalmics, parenterals, nasal sprays, and inhalation formulations. Advanced technologies such as microspheres, nanosuspensions, nano-emulsions, liposomes, and peptides are utilized in manufacturing processes.

Orbicular Pharmaceutical Technologies offers Complex Injectables, Topicals, Ophthalmics, Nasal Sprays, and Inhalations.

Orbicular Pharmaceutical Technologies has 1 investor. Key investors include Tata Capital Healthcare Fund.

Orbicular Pharmaceutical Technologies operates through Orbicular Pharmaceutical Technologies Private Limited.

The legal entities of Orbicular Pharmaceutical Technologies currently have 7 directors, including Hiren Dasharathbhai Patel, Sivaraman Mohan Mailatur, Meena Mohan and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available